International Scholarly Research Notices / 2012 / Article / Tab 1

Clinical Study

Efficacy and Tolerability of Clarema 1% Cream and Hirudoid 40000 U.APTT Gel in the Topical Treatment of Haematomas and/or Subcutaneous Haematic Extravasations

Table 1

Demographic and baseline clinical characteristics. If not otherwise stated, entries are mean and 95% CI.

Heparan sulfateGAGPS

Demographic characteristics
 Gender ( 𝑛 -%):
  males30 (41.7%)21 (43.8%)
  females28 (58.3%)27 (56.3%)
 Age (years)41.9 (37.4 to 46.5)38.3 (34.0 to 42.6)
 Weight (kg)70.9 (67.5 to 74.4)69.8 (66.7 to 72.9)
 Height (cm)172.4 (170.0 to 174.8)172.5 (169.7 to 175.3)
 BMI (cm/m2)23.8 (22.9 to 24.7)23.4 (22.6 to 24.3)

Baseline subjective symptoms and objective signs
 Pain at rest1.3 (1.1 to 1.4)1.2 (1.0 to 1.3)
 Pain at movement2.3 (2.1 to 2.4)2.3 (2.2 to 2.5)
 Functional disability2.1 (2.0 to 2.3)2.3 (2.1 to 2.5)
 Oedema2.4 (2.2 to 2.6)2.5 (2.3 to 2.6)
 Colour of the lesion3.0 (3.0 to 3.0)3.0 (2.9 to 3.0)
 Total score11.1 (10.6 to 11.6)11.2 (10.8 to 11.7)

Size of haematomas/extravasation at baseline
 Minimum diameter (cm)5.7 (5.1 to 6.3)6.0 (5.4 to 6.7)
 Maximum diameter (cm)8.8 (8.1 to 9.6)9.0 (8.1 to 9.9)
 Min*Max diameter (cm2)53.9 (44.4 to 63.4)60.0 (44.0 to 76.1)

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.